secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2022-06-09T23:59:59+00:00
Accession:  0001628280-22-016711
Event type: other
Sentiment:  negative
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

All proposals pass at Cardiff annual meeting; say-on-pay vote splits nearly evenly
--------------------------------------------------------------------------------

- All seven director nominees elected; votes for ranged 14.2M–17.0M, with ~12M broker non-votes.
- BDO USA ratified as auditor: 28.7M for, 487.9K against, 172.4K abstain.
- Amendment to 2021 Omnibus Equity Incentive Plan approved: 14.0M for, 3.1M against, 172.1K abstain.
- Advisory vote on executive compensation approved narrowly: 7.93M for, 7.36M against, 2.02M abstain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000162828022016711/0001628280-22-016711-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000162828022016711/crdf-20220609.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-016711

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer